Best practice RWE approaches to support economic modelling for HTA скачать в хорошем качестве

Best practice RWE approaches to support economic modelling for HTA

How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison? In this webinar, Mtech Access are joined by experts from Arcturis and Delta Hat for a live webinar, where: Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discusses how RWE is assessed by HTA committees Samantha Gillard (Director – HTA, Mtech Access) facilitates the discussion and puts your questions to our experts This webinar was first broadcast live in October 2024. Learn more at https://mtechaccess.co.uk/rwe-approac... For support with real-world evidence analysis, health economic modelling of health technology assessment, email [email protected] or visit https://mtechaccess.co.uk/ Jump to: 00:00 - Welcome and introductions 02:48 - Partitioned survival modelling for HTA and common challenges 03:08 - What is partitioned survival modelling 04:02 - Visualising partitioned survival modelling and estimating health state membership 06:09 - Universal issues in oncology HTA modelling 10:31 - Types of evidence used in oncology modelling 15:37 - What is real-world data? 17:21 - Real-world data to generate an external control arm 17:49 - What is an ECA? 20:12 - ECAs can fill key HTA evidence gaps: Clinical effectiveness 21:48 - ECA case study: ZUMA-5 versus SCHOLAR-5 28:56 - Comparator use and associated costs & ICER influencing model assumptions 30:06 - The HTA reviewers perspective 31:09 - Can HTA bodies accept Real-world data and evidence? 41:10 - Case study - what the NICE committee said 44:11 - Conclusions 46:53 - Reflections and next steps 47:42 - Q&A - Application to non oncology settings 48:02 - Q&A - Use of RWE in the case of missing comparative data in hard to research areas 50:35 - Q&A - Unmet opportunities for HTA agencies with RWE 52:37 - Q&A - RWE changing HTA committee's decision making 53:53 - Q&A - How can RWE contribute to sort of long term monitoring of health technologies post-approval? 55:42 - Q&A - What role can machine learning or AI play when we're generating RWE to support HTA processes?